Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.07.21.739892

From long-term progeny trials to genomic selection: empirical prediction and simulation-guided redesign of Scots pine breeding in Germany

Abstract

Long breeding cycles constrain genetic gain in Scots pine, while mature progeny trials can provide reference populations for genomic selection. We combined phenotypic records from two German trials established in 1990 with dense SNP data. We complemented these data with an offspring-level parentage audit, duplicate filtering, and simulations of breeding strategies. Of 1,986 phenotype-matched genotyped trees, 1,668 formed the parentage-green set and 1,651 remained after exclusion of 17 near-duplicate samples. The final population comprised 1,521 supported controlled-cross offspring and 130 mother-known, father-unknown offspring from 87 progeny labels. Across 14 trait-by-age measurements, GBLUP gave the clearest improvements for diameter and volume from age 20 onwards, whereas height was more mixed. At age 35, ABLUP versus GBLUP heritability was 0.155 versus 0.235 for diameter, 0.265 versus 0.263 for height, and 0.172 versus 0.236 for volume. Leave-progeny-out predictive ability increased from 0.205 to 0.238, 0.249 to 0.265, and 0.203 to 0.239, respectively. SNPscan_breeder simulations compared phenotypic selection, progeny testing, cross-generation genomic selection, and genomic selection with phenotypic thinning under five diversity variants. Progeny testing produced the greatest cumulative gain, but its 45-year cycle reduced annual response. Under the base assumptions, genomic selection with phenotypic thinning gave the highest annual gains for height and fungal resistance, whereas pure genomic selection gave the highest annual diameter gain. Genomic strategies accumulated more kinship than conventional strategies, although a {lambda} = 0.10 kinship penalty improved founder retention with little loss of gain; no mitigation option simultaneously maximised gain, prediction accuracy, and diversity. These results support genomic shortlisting within a field-tested programme with explicit reference-population updating and diversity management.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Degen, B., Leite Montalvao, A. P., Schneck, V.. 2026-07-26. From long-term progeny trials to genomic selection: empirical prediction and simulation-guided redesign of Scots pine breeding in Germany. https://doi.org/10.64898/2026.07.21.739892

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗